Breast
2024 ASCO® Annual Meeting Insights Hub
ASCO 2024 Highlights: Insights From Key Abstracts on mBC
FEATURING
Sramila Aithal
- 195 views
- August 27, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care for Patients With Stage I-III BC"
FEATURING
Marla Lipsyc-Sharf
- 308 views
- July 24, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastatic Breast Cancer - Co-Occurrence and Prevalence Across Treatment"
FEATURING
Manali Bhave
- 468 views
- July 10, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Young-PEARL Study - Palbociclib + Exemestane With GnRH Agonist vs. Capecitabine in Premenopausal Patients With HR+/HER2- mBC"
FEATURING
Yeon Hee Park
- 251 views
- July 10, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clinical Implications"
FEATURING
Sara Tolaney,
Hope Rugo
- 932 views
- July 4, 2024
- 5
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "EMBER Study - Imlunestrant, an Oral SERD, in Combination With HER2 Directed Therapy +/- Abemaciclib in ER+/HER2+ Advanced BC"
FEATURING
Manali Bhave
- 93 views
- July 2, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Management of Higher Risk eBC Including BRCAm, HER2- Subtypes
FEATURING
Milana Dolezal
- 365 views
- July 2, 2024
- 3
ecancer
ASCO® 2024 Insights: "Avelumab in Early TNBC With Residual Disease After Neoadjuvant Chemo or at High Risk After Primary Surgery and Adjuvant Chemo"
FEATURING
Pierfranco Conte
- 71 views
- July 2, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "postMONARCH Trial - Abemaciclib + Fulvestrant vs. Fulvestrant Alone for HR+/HER2- Advanced BC Following Progression on a Prior CDK4/6i + ET"
FEATURING
Kevin Kalinsky
- 363 views
- July 2, 2024
- 1
ecancer
ASCO® 2024 Insights: "Clinical Behavior and Prognostic Impact of Genetic Testing in Young BRCA Breast Cancer Patients"
FEATURING
Matteo Lambertini
- 83 views
- July 2, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breast06, postMONARCH, A-BRAVE, Dato/Durva in I-SPY 2.2, and SACI-IO HR+
FEATURING
Paolo Tarantino
- 2,278 views
- June 21, 2024
- 16
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice
FEATURING
Sara Tolaney,
Hope Rugo
- 4,422 views
- June 7, 2024
- 31
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Updated Survival Data in DESTINY-Breast03 Trial - T-DXd vs. T-DM1 in Patients With HER2+ mBC"
FEATURING
Erika Hamilton
- 367 views
- June 18, 2024
ecancer
ASCO® 2024 Insights: "I-SPY2.2 Trial - Pathologic Response to Neoadjuvant Datopotamab Deruxtecan in Breast Cancer"
FEATURING
Jane Meisel
- 235 views
- June 20, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"
FEATURING
Erika Hamilton
- 1,553 views
- June 18, 2024
- 7
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "H3B-6545 in Women With ER+/HER2- mBC"
FEATURING
Erika Hamilton
- 27 views
- June 18, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Elucidating the Immune Active State of HR+/HER2- MammaPrint High 2 Early BC"
FEATURING
Erin Cobain
- 359 views
- June 18, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
DESTINY-Breast06 - T-DXd vs. Physician’s Choice of Chemotherapy in HR+/HER2-Low/Ultralow mBC After Endocrine Therapy
FEATURING
Giuseppe Curigliano
- 802 views
- June 18, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
Treatment and Outcomes in Select Subpopulations With Breast Cancer
FEATURING
Lisa Carey
- 373 views
- June 18, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "JBCRG-M06/EMERALD Trial - Trastuzumab & Pertuzumab in Combination With Eribulin Mesylate or a Taxane as 1L Chemotherapeutic Treatment for HER2+ Stage 3/4 BC"
FEATURING
Toshinari Yamashita
- 96 views
- June 17, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Ultra-Sensitive ctDNA Mutation Tracking to Identify MRD and Predict Relapse in Patients With Early BC"
FEATURING
Isaac Garcia-Murillas
- 712 views
- June 17, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Development and Validation of RSClinN+ Tool for HR+/HER2- Node-Positive BC
FEATURING
Lajos Pusztai
- 838 views
- June 17, 2024
- 5
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "NATALEE Trial - Baseline Characteristics and Efficacy Outcomes in N0 HR+/HER2- eBC"
FEATURING
Denise Yardley
- 862 views
- June 7, 2024
- 6
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "ACE-Breast-02 Trial - ARX788 vs. Lapatinib + Capecitabine in HER2+ ABC"
FEATURING
Xi-Chun Hu
- 49 views
- June 12, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "I-SPY2.2 Trial - Rates of pCR After Neoadjuvant Datopotamab Deruxtecan for High-Risk Stage 2/3 BC"
FEATURING
Jane Meisel
- 221 views
- June 13, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "PRIMED Trial - Prevention of SG-Related Neutropenia & Diarrhea in Patients With TNBC or HR+/HER2- Advanced BC"
FEATURING
Antonio Llombart-Cussac
- 379 views
- June 11, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "SACI-IO HR+ Trial - Sacituzumab Govitecan +/- Pembro in Patients With HR+/HER2- mBC"
FEATURING
Ana Garrido-Castro
- 277 views
- June 13, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "OPERA-01 Study - Palazestrant (OP-1250) vs. SoC for ER+/HER2- Advanced/Metastatic BC After ET & CDK4/6i"
FEATURING
Barbara Pistilli
- 39 views
- June 11, 2024